ADMA BIOLOGICS, INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
ADMA Biologics reported 2Q26 total revenue of $124.4M (+2% YoY), with ASCENIV revenue of $102.9M (+24% YoY) offsetting BIVIGAM decline of 49% YoY to $19.4M. GAAP net income was $37.8M (+11% YoY); Adjusted EBITDA was $61.8M (+22% YoY). The company repurchased 7.1M shares in Q2 (13.8M YTD, 5.3% of outstanding) and reiterated FY2026 guidance: $530–560M revenue, $170–200M Adjusted Net Income, $265–300M Adjusted EBITDA. Management highlighted real-world evidence from 127 ASCENIV-treated patients showing statistically significant reductions in infection-related hospitalizations and healthcare utilization; abstract submitted to November 2026 ACAAI meeting.
Why this rating
ASCENIV growth is solid but total revenue nearly flat YoY; core market stabilizing, not expanding. Modest event relative to $4.2B market cap.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.